BioSyent
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of BioSyent generated cash of $5,054,974, which is more than the previous year. Cash used in financing activities reached the amount of -$5,784,535 last year. Net change in cash is therefore $119,975.
Cash Flow
| 2014 | 3.64M | -1.07M | 34.25K |
|---|---|---|---|
| 2015 | 2.81M | -5.47M | 18.7K |
| 2016 | 4.39M | 4.23M | 63.56K |
| 2017 | 6.54M | -7.03M | 110.85K |
| 2018 | 6.28M | -1.58M | -505.26K |
| 2019 | 4.77M | -1.68M | -6.38M |
| 2020 | 6.89M | 3.38M | -3.37M |
| 2021 | 4.67M | -4.83M | -2.07M |
| 2022 | 4.94M | -10.79M | -4.37M |
| 2023 | 5.05M | 883.84K | -5.78M |
RX.V Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 7.86M | 18.03M | 20.29M | 13.44M | 16.83M | 12.65M | 13.05M | 4.39M | 6.98M | 4.38M |
Operating activities | ||||||||||
Net income | 6.46M | 5.45M | 6.28M | 3.79M | 4.36M | 5.70M | 5.20M | 4.30M | 3.76M | 3.15M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 455.33K | 450.99K | 457.10K | 510.42K | 291.73K | 185.28K | 189.55K | 146.64K | 61.40K | 45.58K |
Stock-based compensation expense | 513.48K | 439.67K | 334.41K | 266.17K | 263.24K | 0 | 192.58K | 235.47K | 163.56K | 108.20K |
| Deferred income tax benefit | 513.48K | 439.67K | 334.41K | 266.17K | 263.24K | 0 | 192.58K | 235.47K | 163.56K | 108.20K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 241.36K | -426.37K | -1.26M | 650.55K | -352.98K | -32.09K | -281.62K | -555.89K | -744.58K | 0 |
Inventories | -1.48M | -2.43M | -130.77K | 65.56K | -655.73K | -574.56K | 651.22K | 184.88K | -473.02K | -749.12K |
Accounts payable | 14.79K | 1.49M | -160.35K | 942.59K | 123.84K | 108.86K | 410.05K | 153.27K | -17.67K | 1.22M |
Cash generated by operating activities | 5.05M | 4.94M | 4.67M | 6.89M | 4.77M | 6.28M | 6.54M | 4.39M | 2.81M | 3.64M |
Investing activities | ||||||||||
Purchases Of Investments | -2.5M | -10.65M | -4.89M | 0 | -939.32K | -905.84K | -6.00M | 0 | -11.66M | -999.96K |
Investments In Property Plant And Equipment | -174.23K | -519.31K | -93.18K | -174.29K | -734.13K | -504.02K | -640.47K | -405.46K | -1.14M | -75.18K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.01M | 0 |
Cash generated by investing activities | 883.84K | -10.79M | -4.83M | 3.38M | -1.68M | -1.58M | -7.03M | 4.23M | -5.47M | -1.07M |
Financing activities | ||||||||||
Common Stock Issued | 66.85K | 0 | 10.32K | 7.41K | 0 | 100.92K | 110.85K | 63.56K | 18.7K | 0 |
Payments for dividends | -1.91M | -483.95K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -3.69M | -3.68M | -1.84M | -3.14M | -6.35M | -606.19K | 0 | 0 | 0 | 0 |
Repayments of term debt | -174.05K | -161.81K | -151.94K | -144.25K | -23.27K | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | -5.78M | -4.37M | -2.07M | -3.37M | -6.38M | -505.26K | 110.85K | 63.56K | 18.7K | 34.25K |
Net Change In Cash | 119.97K | -10.17M | -2.25M | 6.84M | -3.39M | 4.18M | -404.13K | 8.66M | -2.59M | 2.60M |
Cash at end of period | 7.98M | 7.86M | 18.03M | 20.29M | 13.44M | 16.83M | 12.65M | 13.05M | 4.39M | 6.98M |